OTCPK:NXSC.F

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the United States and Australia. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has Next Science's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: NXSC.F's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

NXSC.F

0.6%

US Medical Equipment

1.3%

US Market


1 Year Return

-54.1%

NXSC.F

17.1%

US Medical Equipment

15.8%

US Market

Return vs Industry: NXSC.F underperformed the US Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: NXSC.F underperformed the US Market which returned 15.8% over the past year.


Shareholder returns

NXSC.FIndustryMarket
7 Day0%0.6%1.3%
30 Day-2.3%-2.4%-4.1%
90 Day-2.1%10.6%8.4%
1 Year-54.1%-54.1%18.1%17.1%18.4%15.8%
3 Yearn/a70.9%66.5%38.2%29.0%
5 Yearn/a144.0%125.3%84.9%64.0%

Price Volatility Vs. Market

How volatile is Next Science's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Next Science undervalued compared to its fair value and its price relative to the market?

12.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate NXSC.F's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate NXSC.F's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: NXSC.F is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: NXSC.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate NXSC.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: NXSC.F is overvalued based on its PB Ratio (12.6x) compared to the US Medical Equipment industry average (4x).


Next Steps

Future Growth

How is Next Science forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

49.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: NXSC.F is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NXSC.F is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NXSC.F is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NXSC.F's revenue (57.9% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: NXSC.F's revenue (57.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NXSC.F's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Next Science performed over the past 5 years?

-33.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: NXSC.F is currently unprofitable.

Growing Profit Margin: NXSC.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NXSC.F is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.

Accelerating Growth: Unable to compare NXSC.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NXSC.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.8%).


Return on Equity

High ROE: NXSC.F has a negative Return on Equity (-98.21%), as it is currently unprofitable.


Next Steps

Financial Health

How is Next Science's financial position?


Financial Position Analysis

Short Term Liabilities: NXSC.F's short term assets ($12.8M) exceed its short term liabilities ($1.8M).

Long Term Liabilities: NXSC.F's short term assets ($12.8M) exceed its long term liabilities ($1.8M).


Debt to Equity History and Analysis

Debt Level: NXSC.F is debt free.

Reducing Debt: NXSC.F had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: NXSC.F has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: NXSC.F has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 9.6% each year.


Next Steps

Dividend

What is Next Science current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate NXSC.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate NXSC.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if NXSC.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NXSC.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NXSC.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Judith Mitchell

3.08yrs

Tenure

US$431,913

Compensation

Ms. Judith Mitchell serves as Managing Director & CEO of Next Science Limited since August 2017 and serves as its a Director since October 20, 2017. Previously, Ms. Mitchell was President, DePuy Synthes As ...


CEO Compensation Analysis

Compensation vs Market: Judith's total compensation ($USD431.91K) is below average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Insufficient data to compare Judith's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Judith Mitchell
MD, CEO & Director3.08yrsUS$431.91k2.51%
$ 4.2m
Matthew Myntti
Founder & CTOno dataUS$349.58k10.98%
$ 18.4m
Jacqueline Butler
Chief Financial Officerno dataUS$210.29kno data
Jon Swanson
Chief Operating Officer2.25yrsUS$341.74kno data
Dustin Haines
Chief Commercial Officer0.25yrno datano data
Gillian Nairn
Company Secretary2.25yrsno datano data

2.3yrs

Average Tenure

Experienced Management: NXSC.F's management team is considered experienced (2.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Judith Mitchell
MD, CEO & Director3.08yrsUS$431.91k2.51%
$ 4.2m
George Savvides
Independent Non-Executive Chairman2.17yrsUS$226.05k0.33%
$ 555.8k
Mark Compton
Independent Non-Executive Director1.92yrsUS$97.12k0.066%
$ 111.1k
Bruce Hancox
Non-Executive Director8.42yrsUS$101.82kno data
Daniel Spira
Independent Non-Executive Director2.92yrsUS$80.89k0.026%
$ 43.8k
Aileen Stockburger
Independent Non-Executive Director1.92yrsUS$97.12k0.024%
$ 39.9k

2.5yrs

Average Tenure

Experienced Board: NXSC.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Next Science Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Next Science Limited
  • Ticker: NXSC.F
  • Exchange: OTCPK
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: AU$237.149m
  • Listing Market Cap: AU$167.360m
  • Shares outstanding: 188.21m
  • Website: https://www.nextscience.com

Location

  • Next Science Limited
  • The Zenith Building, Tower A
  • Suite 1902
  • Sydney
  • New South Wales
  • 2067
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NXSASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 2019
NXSCHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 2019
NXSC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDApr 2019

Biography

Next Science Limited, a medical technology company, researches, develops, and commercializes non-toxic technology products with efficacy in eradicating biofilm based and free-floating bacteria in the Unite ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/29 00:15
End of Day Share Price2020/09/21 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.